Humoral Immunity Elicited by the XBB.1.5 Monovalent COVID-19 Vaccine
Abstract As novel SARS-CoV-2 variants continue to emerge, the updated XBB.1.5 monovalent vaccines remain to be evaluated in terms of immunogenicity against live clinical isolates. We report boosting of IgG(2.1X), IgA(1.5X), and total IgG/A/M(1.7X) antibodies targeting the spike receptor-binding domain and neutralizing titers against WA1(2.2X), XBB.1.5(7.4X), EG.5.1(10.5X), and JN.1(4.7X) variants..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 28. März Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nguyenla, Xammy Huu [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2024.03.25.24304857 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI04305756X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI04305756X | ||
| 003 | DE-627 | ||
| 005 | 20240329090629.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240327s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2024.03.25.24304857 |2 doi | |
| 035 | |a (DE-627)XBI04305756X | ||
| 035 | |a (biorXiv)10.1101/2024.03.25.24304857 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nguyenla, Xammy Huu |e verfasserin |0 (orcid)0000-0002-7532-8356 |4 aut | |
| 245 | 1 | 0 | |a Humoral Immunity Elicited by the XBB.1.5 Monovalent COVID-19 Vaccine |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract As novel SARS-CoV-2 variants continue to emerge, the updated XBB.1.5 monovalent vaccines remain to be evaluated in terms of immunogenicity against live clinical isolates. We report boosting of IgG(2.1X), IgA(1.5X), and total IgG/A/M(1.7X) antibodies targeting the spike receptor-binding domain and neutralizing titers against WA1(2.2X), XBB.1.5(7.4X), EG.5.1(10.5X), and JN.1(4.7X) variants. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Bates, Timothy A. |0 (orcid)0000-0002-2533-7668 |4 aut | |
| 700 | 1 | |a Trank-Greene, Mila |0 (orcid)0009-0000-4934-3811 |4 aut | |
| 700 | 1 | |a Wahedi, Mastura |4 aut | |
| 700 | 1 | |a Tafesse, Fikadu G. |0 (orcid)0000-0002-8575-4164 |4 aut | |
| 700 | 1 | |a Curlin, Marcel |0 (orcid)0000-0003-3481-3889 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 28. März |
| 773 | 1 | 8 | |g year:2024 |g day:28 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2024.03.25.24304857 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 28 |c 03 | ||